Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Middle molecular weight uremic toxins are a heterogeneous class of solutes defined primarily by their molecular weight, typically ranging from 500 Da to 58,000 Da (0.5–58 kDa)[1][2]. This group is subdivided into small-middle (0.5–15 kDa), medium-middle (15–25 kDa), and large-middle (25–58 kDa) solutes. These toxins are clinically significant because their accumulation in kidney failure is associated with inflammation, cardiovascular disease, immunosuppression, and other complications. Notable examples include β2-microglobulin. The class does not refer to a discrete molecular entity or a single receptor, and thus is not conventionally considered a drug target. Instead, clinical intervention focuses on optimizing dialysis modalities that enhance their removal[1][2]. In summary, "Mid-molecular weight toxins" does not refer to a single molecule or receptor and is not a therapeutic target in the conventional sense. It is a functional class relevant to renal failure and dialysis, encompassing a wide spectrum of biologically diverse toxins[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Middle molecular weight uremic toxin.